Literature DB >> 14686736

The early successful treatment of glioblastoma patients with modified boron neutron capture therapy. Report of two cases.

Shinji Kawabata1, Shin-Ichi Miyatake, Yoshinaga Kajimoto, Yuzo Kuroda, Toshihiko Kuroiwa, Yoshio Imahori, Mitsunori Kirihata, Yoshinori Sakurai, Tohru Kobayashi, Koji Ono.   

Abstract

We very effectively treated two patients with recurrent glioblastoma with modified boron neutron capture therapy (BNCT). In this paper, we describe the effectiveness of this treatment, and discuss the ways in which we modified the treatment. A 61-year-old man had a first operation for a right temporal glioblastoma, followed by full-dose chemo-radiotherapy. One year after the operation a partial removal was performed for the recurrent tumor at the same site. Fifty days after the second surgery, the patient received BNCT. We used an epithermal neutron beam as the neutron source, and used both sodium borocapate and boronophenylalanine as boron compounds with the craniotomy. Forty-eight hours after the BNCT, the follow-up MRI was applied to estimate the early effect of this treatment, which showed a 70% reduction in the contrast enhanced lesion, compared with the pretreatment MRI. In addition, the lesion/normal brain ratio of thallium-SPECT had improved markedly. No serial sequelae appeared after this treatment, and the patient remains healthy 6 months after the treatment. A 29-year-old young lady had a right temporal brain tumor, which was partially resected and followed by stereotactic radiosurgery for the residual mass. Seven months after the radiosurgery, a second operation was performed, which revealed the glioblastoma as diagnosis. We applied BNCT uneventfully for this patient with epithermal beam and two kinds of boron compounds as described above. For the treatment of the patient irradiation was applied without craniotomy with marked reduction of tumor volume immediately after the treatment.

Entities:  

Mesh:

Year:  2003        PMID: 14686736     DOI: 10.1023/b:neon.0000003751.67562.8e

Source DB:  PubMed          Journal:  J Neurooncol        ISSN: 0167-594X            Impact factor:   4.130


  12 in total

1.  The combined effect of boronophenylalanine and borocaptate in boron neutron capture therapy for SCCVII tumors in mice.

Authors:  K Ono; S Masunaga; M Suzuki; Y Kinashi; M Takagaki; M Akaboshi
Journal:  Int J Radiat Oncol Biol Phys       Date:  1999-01-15       Impact factor: 7.038

2.  Neutron capture therapy with boron in the treatment of glioblastoma multiforme.

Authors:  L E FARR; W H SWEET; J S ROBERTSON; C G FOSTER; H B LOCKSLEY; D L SUTHERLAND; M L MENDELSOHN; E E STICKLEY
Journal:  Am J Roentgenol Radium Ther Nucl Med       Date:  1954-02

3.  Neuropathologic study of fourteen cases of malignant brain tumor treated by boron-10 slow neutron capture radiation.

Authors:  A K Asbury; R G Ojemann; S L Nielsen; W H Sweet
Journal:  J Neuropathol Exp Neurol       Date:  1972-04       Impact factor: 3.685

4.  Biodistribution of boronophenylalanine in patients with glioblastoma multiforme: boron concentration correlates with tumor cellularity.

Authors:  J A Coderre; A D Chanana; D D Joel; E H Elowitz; P L Micca; M M Nawrocky; M Chadha; J O Gebbers; M Shady; N S Peress; D N Slatkin
Journal:  Radiat Res       Date:  1998-02       Impact factor: 2.841

5.  Boron neutron capture therapy of brain tumors: enhanced survival and cure following blood-brain barrier disruption and intracarotid injection of sodium borocaptate and boronophenylalanine.

Authors:  R F Barth; W Yang; J H Rotaru; M L Moeschberger; C P Boesel; A H Soloway; D D Joel; M M Nawrocky; K Ono; J H Goodman
Journal:  Int J Radiat Oncol Biol Phys       Date:  2000-04-01       Impact factor: 7.038

6.  Boron neutron-capture therapy (BNCT) for glioblastoma multiforme (GBM) using the epithermal neutron beam at the Brookhaven National Laboratory.

Authors:  M Chadha; J Capala; J A Coderre; E H Elowitz; J Iwai; D D Joel; H B Liu; L Wielopolski; A D Chanana
Journal:  Int J Radiat Oncol Biol Phys       Date:  1998-03-01       Impact factor: 7.038

7.  Positron emission tomography-based boron neutron capture therapy using boronophenylalanine for high-grade gliomas: part I.

Authors:  Y Imahori; S Ueda; Y Ohmori; K Sakae; T Kusuki; T Kobayashi; M Takagaki; K Ono; T Ido; R Fujii
Journal:  Clin Cancer Res       Date:  1998-08       Impact factor: 12.531

Review 8.  The radiation biology of boron neutron capture therapy.

Authors:  J A Coderre; G M Morris
Journal:  Radiat Res       Date:  1999-01       Impact factor: 2.841

Review 9.  Boron neutron capture therapy for malignant gliomas.

Authors:  A Z Diaz; J A Coderre; A D Chanana; R Ma
Journal:  Ann Med       Date:  2000-02       Impact factor: 4.709

10.  Radiobiological evidence suggesting heterogeneous microdistribution of boron compounds in tumors: its relation to quiescent cell population and tumor cure in neutron capture therapy.

Authors:  K Ono; S I Masunaga; Y Kinashi; M Takagaki; M Akaboshi; T Kobayashi; K Akuta
Journal:  Int J Radiat Oncol Biol Phys       Date:  1996-03-15       Impact factor: 7.038

View more
  14 in total

1.  Cerebrospinal fluid dissemination of high-grade gliomas following boron neutron capture therapy occurs more frequently in the small cell subtype of IDH1R132H mutation-negative glioblastoma.

Authors:  Natsuko Kondo; Rolf F Barth; Shin-Ichi Miyatake; Shinji Kawabata; Minoru Suzuki; Koji Ono; Norman L Lehman
Journal:  J Neurooncol       Date:  2017-05-22       Impact factor: 4.130

2.  Preferential recurrence of a sarcomatous component of a gliosarcoma after boron neutron capture therapy: case report.

Authors:  Shin-Ichi Miyatake; Hiroko Kuwabara; Yoshinaga Kajimoto; Shinji Kawabata; Kunio Yokoyama; Atsushi Doi; Motomu Tsuji; Hiroshi Mori; Koji Ono; Toshihiko Kuroiwa
Journal:  J Neurooncol       Date:  2006-01       Impact factor: 4.130

3.  Determining a methodology of dosimetric quality assurance for commercially available accelerator-based boron neutron capture therapy system.

Authors:  Katsumi Hirose; Takahiro Kato; Takaomi Harada; Tomoaki Motoyanagi; Hiroki Tanaka; Akihiko Takeuchi; Ryohei Kato; Shinya Komori; Yuhei Yamazaki; Kazuhiro Arai; Noriyuki Kadoya; Mariko Sato; Yoshihiro Takai
Journal:  J Radiat Res       Date:  2022-07-19       Impact factor: 2.438

4.  Survival benefit of Boron neutron capture therapy for recurrent malignant gliomas.

Authors:  Shin-Ichi Miyatake; Shinji Kawabata; Kunio Yokoyama; Toshihiko Kuroiwa; Hiroyuki Michiue; Yoshinori Sakurai; Hiroaki Kumada; Minoru Suzuki; Akira Maruhashi; Mitsunori Kirihata; Koji Ono
Journal:  J Neurooncol       Date:  2008-09-24       Impact factor: 4.130

5.  Evaluation of fluoride-labeled boronophenylalanine-PET imaging for the study of radiation effects in patients with glioblastomas.

Authors:  Minoru Miyashita; Shin-Ichi Miyatake; Yoshio Imahori; Kunio Yokoyama; Shinji Kawabata; Yoshinaga Kajimoto; Masa-Aki Shibata; Yoshinori Otsuki; Mitsunori Kirihata; Koji Ono; Toshihiko Kuroiwa
Journal:  J Neurooncol       Date:  2008-06-20       Impact factor: 4.130

6.  Pseudoprogression in boron neutron capture therapy for malignant gliomas and meningiomas.

Authors:  Shin-Ichi Miyatake; Shinji Kawabata; Naosuke Nonoguchi; Kunio Yokoyama; Toshihiko Kuroiwa; Hideki Matsui; Koji Ono
Journal:  Neuro Oncol       Date:  2009-03-16       Impact factor: 12.300

7.  Tumor-specific targeting of sodium borocaptate (BSH) to malignant glioma by transferrin-PEG liposomes: a modality for boron neutron capture therapy.

Authors:  Atsushi Doi; Shinji Kawabata; Kyoko Iida; Kunio Yokoyama; Yoshinaga Kajimoto; Toshihiko Kuroiwa; Takashi Shirakawa; Mitsunori Kirihata; Satoshi Kasaoka; Kazuo Maruyama; Hiroaki Kumada; Yoshinori Sakurai; Shin-Ichiro Masunaga; Koji Ono; Shin-Ichi Miyatake
Journal:  J Neurooncol       Date:  2008-01-25       Impact factor: 4.130

Review 8.  Boron neutron capture therapy for malignant brain tumors.

Authors:  Shin-Ichi Miyatake; Masahiko Wanibuchi; Naonori Hu; Koji Ono
Journal:  J Neurooncol       Date:  2020-07-16       Impact factor: 4.130

9.  Pharmacokinetic study of BSH and BPA in simultaneous use for BNCT.

Authors:  Kunio Yokoyama; Shin-Ichi Miyatake; Yoshinaga Kajimoto; Shinji Kawabata; Atsushi Doi; Toshiko Yoshida; Tomoyuki Asano; Mitsunori Kirihata; Koji Ono; Toshihiko Kuroiwa
Journal:  J Neurooncol       Date:  2006-03-24       Impact factor: 4.130

10.  Accelerator-based BNCT for patients with recurrent glioblastoma: a multicenter phase II study.

Authors:  Shinji Kawabata; Minoru Suzuki; Katsumi Hirose; Hiroki Tanaka; Takahiro Kato; Hiromi Goto; Yoshitaka Narita; Shin-Ichi Miyatake
Journal:  Neurooncol Adv       Date:  2021-05-20
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.